SCHEMBL856025

SCHEMBL856025

O=C1OCc2c(F)cccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.47
MAOA P21397 1/20 0.47
TYMS P04818 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KCNJ1 P48048 3/20 0.43
SRD5A1 P18405 1/20 0.40
CYP19A1 P11511 2/20 0.39
KCNH2 Q12809 2/20 0.39
MAPK1 P28482 1/20 0.37
TYR P14679 1/20 0.37
IKBKB O14920 1/20 0.37
ALOX5 P09917 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19681499 0.78 PGR (0.51) SRD5A1CYP19A1
SCHEMBL855513 0.78 KCNJ1 (0.46) MAOBMAOATYMSKDM4EALDH1A1
SCHEMBL1265831 0.76 MAPK1 (0.39) TYMSSRD5A1CYP19A1MAPK1TYR
SCHEMBL78594 0.75 MAOB (0.47) MAOBMAOATYMSKDM4EALDH1A1
SCHEMBL2045834 0.75 MAOB (0.47) MAOBMAOATYMSKDM4EALDH1A1
SCHEMBL32672785 0.75 MAOB (0.47) MAOBMAOATYMSKDM4EALDH1A1
SCHEMBL698199 0.75 PIM1 (0.48) MAOBMAOATYMSKDM4EALDH1A1
SCHEMBL87504 0.75 MAOB (0.47) MAOBMAOATYMSKDM4EALDH1A1
SCHEMBL7639394 0.75 KCNJ1 (0.51) MAOBMAOATYMSKDM4EALDH1A1
SCHEMBL30991499 0.75 MAOB (0.47) MAOBMAOATYMSKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10925967-B2 Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-02-23 US disclosed
US-10646575-B2 Heterocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-05-12 US disclosed
US-20190262459-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. 2019-08-29 US disclosed
US-20190076541-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 US disclosed
US-8604221-B2 Production method of halogen-substituted phthalide SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-12-10 US disclosed
US-20120142946-A1 PRODUCTION METHOD OF HALOGEN-SUBSTITUTED PHTHALIDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-06-07 US disclosed
EP-2433933-A1 PRODUCTION METHOD OF HALOGEN-SUBSTITUTED PHTHALIDE Sumitomo Chemical Company, Limited (JP) 2012-03-28 EP disclosed
CN-100430390-C Water-soluble triazole antifungal agents SANKYO CO (JP) 2008-11-05 CN disclosed
EP-1362856-B1 WATER-SOLUBLE TRIAZOLE FUNGICIDE DAIICHI SANKYO CO LTD (JP) 2008-09-10 EP disclosed
CN-100349569-C Water-soluble triazole fungicide SANKYO CO (JP) 2007-11-21 CN disclosed
US-7230023-B2 Water-soluble triazole fungicide SANKYO COMPANY, LIMITED (JP) 2007-06-12 US disclosed
CN-1720913-A Water-soluble triazole fungicide SANKYO CO (JP) 2006-01-18 CN disclosed
US-20040198790-A1 Water-soluble triazole fungicide SANKYO COMPANY, LIMITED (JP) 2004-10-07 US disclosed
CN-1503795-A Water-soluble triazole antifungal agents ������������ʽ���� 2004-06-09 CN disclosed
EP-1362856-A1 WATER-SOLUBLE TRIAZOLE FUNGICIDE Sankyo Company, Limited (JP) 2003-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10646575-B2 Heterocyclic degronimers for target protein degradation CRBN, MDM2, STUB1 MAOB 3539/4885MAOA 3304/4885TYMS 3180/4885
US-20040198790-A1 Water-soluble triazole fungicide ERG28, CYP51A1, XDH MAOB 1364/4885MAOA 1236/4885TYMS 3915/4885
US-20190076541-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION CRBN, MDM2, STUB1 MAOB 3539/4885MAOA 3304/4885TYMS 3180/4885
US-20190262459-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BTK, CBL, SYK MAOB 1663/4885MAOA 2361/4885TYMS 1290/4885
US-10925967-B2 Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use BTK, CBL, SYK MAOB 1663/4885MAOA 2361/4885TYMS 1290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.